Biotech Startups

Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism. Its pipeline of cardio-hematology programs targets patients requiring time-sensitive thrombolytic intervention or management of thrombosis risk.

1 investor

ArrePath is a biotechnology company that applies AI/ML to drug discovery and development. The company leverages computational platforms and data science to accelerate the identification and advancement of new therapeutic candidates across multiple disease areas.

1 investor

1 investor

Arrivo Bio develops novel, disease-modifying medicines targeting the root cause of hard-to-treat diseases for which few effective treatment options exist. The company partners with Mayo Clinic and Daiichi Sankyo to advance first-of-its-kind therapies.

1 investor

ArrowBiome develops a microbiome platform technology with clinical validation and MIT-originated intellectual property, serving the beauty and ingredients industries. The company has demonstrated commercial traction with 47 engagements across 19 markets and is advancing toward profitability through its product applications.

1 investor

Arrowsmith Genetics is a preclinical-stage drug discovery company developing therapeutics from genetic research conducted at UBC and BC Cancer. The company was founded to advance potential treatments derived from 20+ years of scientific insights in cancer and genetic biology.

1 investor

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression. Its lead candidate AX-158 has shown Phase 2a data in psoriasis, with additional Phase 2 trials planned in atopic dermatitis and rheumatoid arthritis.

1 investor

Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition. Its lead molecule, AR882, is a urate-lowering agent aimed at reducing uric acid, tophi, and gout flares.

1 investor

1 investor

Artidis develops nanomechanical imaging technology for rapid cancer diagnosis and treatment optimization in clinical settings. The company's diagnostic platform aims to help clinicians with faster, more accurate cancer assessment and prognosis.

1 investor

Artielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.

1 investor

ArtiFex Medical develops vascular grafts made from bacterial cellulose for small-diameter vascular access. The company provides a biocompatible material solution for vascular applications in the medical device sector.

1 investor

Artis BioSolutions develops synthetic DNA and provides integrated manufacturing services for genetic medicine and advanced therapeutic modalities, including cell therapy, gene therapy, mRNA, gene editing, and vaccines. The company serves genetic medicine developers seeking to accelerate clinical development and GMP manufacturing within a single quality framework.

1 investor

ARTIS Ventures is a venture capital firm investing in frontier technologies and breakthroughs primarily at the intersection of technology, biology, and healthcare. The firm backs early-stage companies across biotech, life sciences, and health technology sectors, with a portfolio spanning therapeutics, digital health, and medical devices.

1 investor

Artivila is an AI-driven pharmaceutical research and development company that uses artificial intelligence and computational chemistry to accelerate drug discovery across oncology, autoimmune diseases, and neurodegenerative diseases. The platform combines AI target identification, lead compound design, and clinical candidate selection to develop novel therapeutics for unmet patient needs.

1 investor

Arul Health is building a patient navigation service that bridges healthcare and social care, helping people with serious diagnoses coordinate care, advocate on their behalf, and contest costs. It supports patients and their families through the practical and emotional challenges of illness.

1 investor

Arxada develops microbial control and antimicrobial technologies for professional hygiene, paints, coatings, wood protection, home and personal care, and human health applications. The company serves industrial and consumer end markets with chemistry-based solutions that support product safety and performance.

1 investor

Ascelia Pharma is a biotech company developing and commercializing drugs for rare, orphan oncology-related conditions with unmet medical needs. Its clinical-stage pipeline includes Orviglance, an oral MRI contrast agent for detecting liver lesions, and Oncoral, an oral chemotherapy tablet for gastric cancer.

1 investor

Ascendia Pharmaceutical Solutions is a contract development and manufacturing organization (CDMO) that provides formulation, nanotechnology, and manufacturing services for pharmaceutical and biological companies from pre-formulation through commercialization. The company specializes in solving drug development challenges for small molecules, biologics, and gene delivery applications.

1 investor

Ascidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.

1 investor

Asclepii makes Poseidon, an FDA-cleared nanosilver hydrogel wound dressing that maintains a moist wound environment and blocks microbes for topical wound management. It is used by clinicians such as podiatrists and nurses for chronic and everyday wound care.

1 investor

Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.

1 investor

Asha Therapeutics uses physics-based computational methods to design drug molecules, operating at the intersection of computational chemistry and drug discovery. The company's approach aims to reduce time and cost in early-stage pharmaceutical development.

1 investor

āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers. Its lead product is the antibody andecaliximab.

1 investor